Food and snack companies may feel the most pressure as weight-loss drugs become more mainstream and impact consumer behaviors, according to Bank of America. Diabetes drugs that mimic gut hormones such as glucagon-like peptide-1, or GLP-1, have found new audiences in people looking to lose weight. In some instances, people taking these medicines have reported less of a hankering for unhealthy foods or alcohol and other drinks.
Pro compiled some of the stocks that could be at risk that the firm is watching. All data is from LSEG and current as of Friday morning: — 's Michael Bloom contributed to this report
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »